Research progress of neoadjuvant therapy for borderline resectable pancreatic cancer / 医学研究生学报

ABSTRACT

Pancreatic cancer is known as one of the most fatal malignant diseases in digestive system.Approximately 15%-20%of patients are deemed resectable at the time of diagnosis.Neoadjuvant therapy to the borderline resectable pancreatic cancer ( BRPC) has been challenged to achieve down-staging of cancer, to avoid unnecessary major operation if the pancreatic cancer progres-ses and distant metastasis develops during preoperative treatment.However, there are some controversial issues influencing the clinical decision of surgeon in managing BRPC.This manuscript reviews the current controversial issues in managing BRPC in order to enhance proper understanding for the current status and potential role of neoadjuvant therapy in managing BRPC.